Shilpa Medicare and Orion partner, expanding into European market
Ella Day | June 16, 2025 | News story | Manufacturing and Production | Corporate, Orion Corporation, Shilpa Biocare, Shilpa Medicare, commercial supply agreement, plasma protein, recombinant human albumin
Shilpa Biocare, a wholly owned subsidiary of Shilpa Medicare, has signed a commercial supply agreement with Finland-based Orion Corporation for its recombinant human albumin. The agreement, announced ahead of the BIO International Convention in Boston, US, grants Orion exclusive rights to distribute, market and sell the product across Europe.
Recombinant human Aabumin is a synthetic version of a key plasma protein used in numerous therapeutic applications. Shilpa’s version is currently under development and will be manufactured using a non-human expression system, enhancing safety, scalability and ensuring virus-free production – addressing limitations associated with plasma-derived albumin.
“We are pleased to strengthen our strategic partnership with Shilpa by collaborating on this novel product,” said Satu Ahomäki, executive vice president, generics and consumer health at Orion. “Recombinant human albumin will strengthen our strategy and offering in value-add hospital generics.”
Under the agreement, Shilpa will receive development and regulatory milestone payments from Orion. The partnership is expected to support Shilpa’s presence in regulated markets and expand its European footprint.
“Partnering with Orion is a significant step in bringing our product to patients across Europe,” said Madhav Bhutada, managing director of Shilpa.
Shilpa, which has commercial facilities for both mammalian and microbial production, anticipates further interest from biopharma innovators, particularly smaller biotech firms, at the BIO International Convention.
Ella Day
16/6/25
